Trial Profile
A Phase II Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2019
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Carboplatin (Primary) ; Pegfilgrastim
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 18 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Apr 2015, as reported by ClinicalTrials.gov.
- 10 Sep 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.